Evolution of the Average Target: Charles River Laboratories International, Inc.

Evolution of the Target Price: Charles River Laboratories International, Inc.

Changes in Analyst Recommendations: Charles River Laboratories International, Inc.

58f6b39c055fc2448290c0df8.OPcdzIdqN65bE9m8V8sci_9jr7if8Li65ylnCxaeALQ.Yo5x9O8te-krVbruJpFT284nl8n1nuDbjRgCM1LTdeMAx1n59itGnBcnmA~9f316c751e77009058feeedd34a4c39b
28/09 Jefferies Adjusts PT on Charles River Laboratories International to $340 From $305, Maintains Buy Rating MT
25/09 Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says MT
25/09 Deutsche Bank Raises Price Target on Charles River Laboratories International to $320 From $300, Keeps Buy Rating MT
25/09 RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating MT
25/09 Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating MT
25/09 Mizuho Adjusts PT on Charles River Laboratories International to $295 From $264, Keeps Neutral Rating MT
25/09 Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating MT
25/09 TD Cowen Adjusts PT on Charles River Laboratories International to $325 From $300, Maintains Buy Rating MT
25/09 Baird Adjusts PT on Charles River Laboratories International to $334 From $291, Keeps Outperform Rating MT
17/09 Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating MT
11/09 Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating MT
10/08 TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating MT
10/08 Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating MT
06/08 Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220 MT
06/08 RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating MT
06/08 Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating MT
06/08 Analyst recommendations: AppLovin, Emerson Electric, Roblox, Flutter Entertainment, HubSpot... Zonebourse
06/08 JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180 MT
20/07 Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… Zonebourse
13/07 BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 MT
13/07 Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating MT
13/07 Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating MT
09/07 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07/07 Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
01/07 Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+17.8%
+3.17%
+27.25%
+17.93%
+50.19%
-5.54%
-19.42%
-8.23%
+34.94%
Average +13.12%
Weighted average by Cap. +16.37%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
294.59USD
Average target price
301.29USD
Spread / Average Target
+2.27%
High Price Target
340.00USD
Spread / Highest target
+15.41%
Low Price Target
145.00USD
Spread / Lowest Target
-50.78%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA
  1. Stock Market
  2. Stocks
  3. CRL Stock
  4. RV6 Stock
  5. Consensus Charles River Laboratories International, Inc.